Characterization of the Monomeric and Dimeric Forms of Latent and Active Matrix Metalloproteinase-9

Matrix metalloproteinase-9 (MMP-9) is a member of the MMP family that has been associated with degradation of the extracellular matrix in normal and pathological conditions. A unique characteristic of MMP-9 is its ability to exist in a monomeric and a disulfide-bonded dimeric form. However, there exists a paucity of information on the properties of the latent (pro-MMP-9) and active MMP-9 dimer. Here we report the purification to homogeneity of the monomer and dimer forms of pro-MMP-9 and the characterization of their biochemical properties and interactions with tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. Gel filtration and surface plasmon resonance analyses demonstrated that the pro-MMP-9 monomeric and dimeric forms bind TIMP-1 with similar affinities. In contrast, TIMP-2 binds only to the active forms. After activation, the two enzyme forms exhibited equal catalytic competence in the turnover of a synthetic peptide substrate with comparable kinetic parameters for the onset of inhibition with TIMPs and for dissociation of the inhibited complexes. Kinetic analyses of the activation of monomeric and dimeric pro-MMP-9 by stromelysin 1 revealed K m values in the nanomolar range and relative low k catvalues (1.9 × 10−3 and 4.1 × 10−4s−1, for the monomer and dimer, respectively) consistent with a faster rate (1 order of magnitude) of activation of the monomeric form by stromelysin 1. This suggests that the rate-limiting event in the activation of pro-MMP-9 may be a requisite slow unfolding of pro-MMP-9 near the site of the hydrolytic cleavage by stromelysin 1.

[1]  R. Fridman,et al.  Kinetic Analysis of the Binding of Human Matrix Metalloproteinase-2 and -9 to Tissue Inhibitor of Metalloproteinase (TIMP)-1 and TIMP-2* , 1997, The Journal of Biological Chemistry.

[2]  Kenneth G. Mann,et al.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes , 1990 .

[3]  R. Muschel,et al.  Developmental expression of MMP‐9 (gelatinase B) mRNA in mouse embryos , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[4]  M. Baumann,et al.  Human gelatinase/type IV procollagenase is a regular plasma component , 1989, FEBS letters.

[5]  W. Bode,et al.  The C‐terminal (haemopexin‐like) domain structure of human gelatinase A (MMP2): structural implications for its function , 1996, FEBS letters.

[6]  A. Strongin,et al.  Human 92 kDa type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. , 1993, Kidney international.

[7]  B C Finzel,et al.  Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity , 1998, Protein science : a publication of the Protein Society.

[8]  U. Moll,et al.  Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. , 1990, Cancer research.

[9]  T. Ackermann C. L. Brooks III, M. Karplus, B. M. Pettitt. Proteins: A Theoretical Perspective of Dynamics, Structure and Thermodynamics, Volume LXXI, in: Advances in Chemical Physics, John Wiley & Sons, New York 1988. 259 Seiten, Preis: US $ 65.25 , 1990 .

[10]  J. Springer,et al.  Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme , 1995, Protein science : a publication of the Protein Society.

[11]  G Murphy,et al.  Tissue inhibitors of matrix metalloendopeptidases. , 1995, Methods in enzymology.

[12]  G. González-Ávila,et al.  Changes in Matrix Metalloproteinases during the Evolution of Interstitial Renal Fibrosis in a Rat Experimental Model , 1998, Pathobiology.

[13]  J. Bousquet,et al.  Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. , 1997, American journal of respiratory cell and molecular biology.

[14]  C. Walsh,et al.  The behavior and significance of slow-binding enzyme inhibitors. , 2006, Advances in enzymology and related areas of molecular biology.

[15]  M. Ågren,et al.  Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans , 1998, The British journal of surgery.

[16]  H. Sengeløv,et al.  Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. , 1993, The Journal of biological chemistry.

[17]  A. Eisen,et al.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Karplus,et al.  Proteins: A Theoretical Perspective of Dynamics, Structure, and Thermodynamics , 1988 .

[19]  J. Enghild,et al.  Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. , 1992, The Journal of biological chemistry.

[20]  Y. Sun,et al.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.

[21]  G. Fields,et al.  Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). , 1994, The Journal of biological chemistry.

[22]  H. Tschesche,et al.  A 25 kDa α2‐microglobulin‐related protein is a component of the 125 kDa form of human gelatinase , 1992, FEBS letters.

[23]  R. Langer,et al.  Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing , 1996, Journal of cellular biochemistry.

[24]  A. Eisen,et al.  SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. , 1989, The Journal of biological chemistry.

[25]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[26]  A. Strongin,et al.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. , 1992, The Journal of biological chemistry.

[27]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[28]  J. Sipley,et al.  Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.

[29]  L. Liotta,et al.  Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. , 1992, The Journal of biological chemistry.

[30]  A. Koch,et al.  Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[31]  J. O'Connell,et al.  Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. , 1994, The Journal of biological chemistry.

[32]  B. Glick,et al.  A graphical method for extracting rate constants from some enzyme-catalyzed reactions not monitored to completion. , 1978, Canadian journal of biochemistry.

[33]  W. Pearce,et al.  Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. , 1997, Surgery.

[34]  R. Fridman,et al.  Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. , 1997, Cancer research.

[35]  M. Maccoss,et al.  Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. , 1997, Journal of medicinal chemistry.

[36]  T. Howard,et al.  Evidence of a role for matrix metalloproteinases in cold preservation injury of the liver in humans and in the rat , 1997, Hepatology.

[37]  K. Shirato,et al.  Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. , 1997, American journal of respiratory cell and molecular biology.

[38]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[39]  R. Fridman,et al.  Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). , 1995, Cancer research.

[40]  E. Lattman,et al.  Crystal structure of the haemopexin-like C-terminal domain of gelatinase A , 1995, Nature Structural Biology.

[41]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[42]  L. Liotta,et al.  Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. , 1990, Cancer research.

[43]  C. López-Otín,et al.  The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. , 1996, Journal of molecular biology.

[44]  G Murphy,et al.  A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases , 1992, FEBS letters.

[45]  C. G. Knight [2] Fluorimetric assays of proteolytic enzymes , 1995 .

[46]  G. Murphy,et al.  Gelatinases A and B. , 2002, Methods in enzymology.

[47]  T. Thompson,et al.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. , 1998, The American journal of pathology.

[48]  L. Kotra,et al.  Matrix metalloproteinases: structures, evolution, and diversification , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  R. Muschel,et al.  Metalloproteinases in tumor progression: the contribution of MMP-9. , 1994, Invasion & metastasis.

[50]  Thiennu H. Vu,et al.  Gelatinase B: Structure, Regulation, and Function , 1998 .

[51]  C. Overall,et al.  Specific, High Affinity Binding of Tissue Inhibitor of Metalloproteinases-4 (TIMP-4) to the COOH-terminal Hemopexin-like Domain of Human Gelatinase A , 1997, The Journal of Biological Chemistry.

[52]  I. Campbell,et al.  Solution structure of a type 2 module from fibronectin: implications for the structure and function of the gelatin-binding domain. , 1997, Structure.